Berlin, Germany - BEBIG Medical, a distinguished global provider of high-quality radiation therapy products, is delighted to announce BEBIG Medical has been awarded contracts to deliver 5 units of HDR (High Dose Rate) brachytherapy equipment to hospitals across the Uzbekistan by the United Nations Office for Project Services (UNOPS).

Uzbekistan, with a total population of 36,020,000, is experiencing rapid development coupled with a notable surge in cancer incidence and mortality rates. In 2018 alone, there were 25,309 reported cancer cases, resulting in 16,685 deaths, with cancer contributing to 15.4% of premature deaths due to non-communicable diseases (NCDs). National monitoring data from the Uzbekistan Ministry of Health reveals a concerning rise in cancer prevalence, exemplified by a tripling of breast cancer cases in the Bukhara area.

The six major cancers posing high mortality and morbidity rates in Uzbekistan are breast (13.9%), cervical (6.4%), lung (9%), liver (5.7%), stomach (10%), and colorectal cancers (6.7%).

Radiotherapy, a pivotal component of cancer care, is integral to the treatment of 40% of patients who achieve a cure. The Medical Devices market in Uzbekistan is projected to reach US$212.90 million in 2023, with an expected annual growth rate (CAGR 2023-2028) of 10.50%. Recognizing the growing need for enhanced radiotherapy infrastructure, Uzbekistan sought support from the International Atomic Energy Agency (IAEA) to provide safe and effective cancer treatment. George Chan, Chairman and CEO at BEBIG Medical, emphasizes the company's dedication to advancing healthcare, aligning seamlessly with the UNOPS mission. He states, "Together, we look forward to leaving an indelible mark on the landscape of cancer care in Uzbekistan."

关于上海惠影医疗

上海惠影医疗科技有限公司（简称“惠影医疗”）是一家专注于肿瘤放射治疗医疗器械技术研发、生产和全球销售跨国企业，总部在中国上海。

惠影医疗于2018年在上海成立，致力于肿瘤放射治疗的技术研发、引进、生产和全球销售。2019年惠影医疗与全球近距离放疗产品三大巨头之一的德国Eckert & Ziegler BEBIG GmbH在中国成立合资公司，技术引进、本地生产和销售高剂量率后装机肿瘤放疗系统，正式启动肿瘤放射治疗领域的业务布局。随后，惠影医疗于2021年对Eckert & Ziegler BEBIG GmbH下属高剂量近距离放疗产品线全球业务进行收购，收购后沿用其原有品牌名BEBIG, 并公司更名为BEBIG Medical，加速布局肿瘤放射治疗领域。2022年，惠影医疗完成对德国公司Wolf- Medizintechnik GmbH (“WOmed”) 的收购，再次拓展X射线治疗和术中放疗产品线。

惠影医疗凭借技术创新和国际并购，持续拓展肿瘤放射治疗医疗器械产品管线和全球营销网络。目前惠影医疗在中国、德国、美国均设有工厂，并在中国、德国、美国、新加坡、印度设有运营公司和办事处，全球员工超过100人，其旗下高剂量近距离放疗产品、X射线治疗产品和术中放疗产品均获得CE、FDA及多国认证，并在全球超过70个国家和地区进行销售，总计活跃装机超过700台。未来，惠影医疗还将凭借其产品实力，加速深化肿瘤放射治疗医疗器械布局，推动其解决方案落地全球市场。

了解更多信息请访问网站 www.bebigmedicalgroup.com.cn